Tuberculous bursitis of the wrist after anti-TNFalpha treatment: a case report

Avgoustidis Nestor 1 , Sipsas Nikolaos 1 , Evangelou Konstantinos 2 ,  and Pikazis Dimitrios 1
  • 1 Pathophysiology Department, Laikon General Hospital and Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece
  • 2 1st Department of Pathology, Laiko General Hospital, National and Kapodistrian University of Athens, 11527, Athens, Greece

Abstract

In this report, we describe a case of tuberculous bursitis-osteomyelitis of the wrist, in an elderly patient with rheumatoid arthritis and anti-TNFalpha (anti-Tumor Necrosis Factor alpha) treatment.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P., Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register, Arthritis Rheum., 2006, 54, 2368–76 http://dx.doi.org/10.1002/art.21978

  • [2] Perez J.L., et. al., Impact of screening for latent tuberculosis prior to initiation anti-TNF therapy in North America and Europe. Ann Rheum Dis., 2005, 64, (Suppl III.), 86

  • [3] Winthrop K.L., Jeffrey N.S., Jereb J., Taylor Z., Iademarco M.F., Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum., 2005, 52, 2968–2974 http://dx.doi.org/10.1002/art.21382

  • [4] American Thoracic Society., Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med., 2000, 161, 221–247

  • [5] Ehlers S., Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanrecept? Clin Infect Dis., 2005, 41 (Suppl 3.), 199–203 http://dx.doi.org/10.1086/429998

  • [6] Winthrop K.L., Yamashita S., Beekman S.E., Polgreen P.M., Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies; case finding through the emerging infections network. Clinical Infectious Disease., 2008, 46, 1738–40 http://dx.doi.org/10.1086/587989

  • [7] Sentruk N., Sahin S., Kocagoz T., Polymerase chain reaction in cutaneous tuberculosis: is it a reliable diagnostic method in paraffin-embedded tissue? Int J Dermatol., 2002, 41, 863–6 http://dx.doi.org/10.1046/j.1365-4362.2002.01604.x

  • [8] Pai M et. al., Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis., 2004, 4, 761–776 http://dx.doi.org/10.1016/S1473-3099(04)01206-X

  • [9] Nahid P., Pai M., Hopewell P.C., Advances in the diagnosis and treatment of tuberculosis. Am Thorac Soc., 2006, 3, 103–10 http://dx.doi.org/10.1513/pats.200511-119JH

  • [10] Jaovisidha S., Chen C., Ruy K.N., Siriwongpairat P., Pekanan P., Sartoris DJ., et. all., Tuberculous tenosynovitis and bursitis: imaging findings in 21 cases. Radiology., 1996, 201, 507–13

  • [11] World Health Organization-third edition., 2003, Treatment of Tuberculosis, Guidelines for National Programmes. Treatment of extra pulmonary tuberculosis (4.10)

OPEN ACCESS

Journal + Issues

Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The journal aims to promote knowledge that is directly relevant to all fields of Medical Science.

Search